Bridge Biotherapeutics Signs an AI-Based Research Agreement with Atomwise to Expand its Pellino Inhibitor Portfolio

 Bridge Biotherapeutics Signs an AI-Based Research Agreement with Atomwise to Expand its Pellino Inhibitor Portfolio

Bridge Biotherapeutics Signs an AI-Based Research Agreement with Atomwise to Expand its Pellino Inhibitor Portfolio

Shots:

  • Atomwise to receive ~ $1.08B as an up front, milestones and royalties on the success of the programs and will utilize its AI technology to evaluate Pellino E3 ubiquitin ligase and other targets nominated by Bridge
  • The collaboration will discover and develop up to 13 small molecule programs across multiple therapeutic areas including inflammatory diseases
  • Bridge’s BBT-401 is a Pellino-1 peptide inhibitor and is currently being evaluated in P-II study for UC. The collaboration will expand Bridge’s portfolio of Pellino inhibitors and allow the company to utilize Atomwise’ AI technology to unlock the discovery of new candidates with exciting targets

Click here ­to­ read full press release/ article | Ref: Atomwise  | Image: Bridge Biotherapeutics

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post